CorMedix Therapeutics Price Target and Financial Performance Overview

Core Insights - CorMedix Therapeutics (NASDAQ: CRMD) is focused on developing therapeutic products for life-threatening diseases, with a new price target set at $16 by Truist Financial, indicating an 84.95% potential upside from its current trading price of $7.44 [1][6] Financial Performance - The company reported preliminary unaudited net revenue of approximately $127 million for Q4 2025 and $400 million for the full year 2025, reflecting its core business activities [3][6] - CorMedix expects its adjusted EBITDA for Q4 to be between $77 million and $81 million, indicating strong operational performance [4][6] - The company has unaudited cash and short-term investments of approximately $148 million, showcasing a solid financial position [4] Market Activity - CRMD's market capitalization is approximately $579.5 million, with a trading volume of 20.76 million shares [5] - The stock has experienced significant volatility, with a current price of $7.36, down 34.15% from a previous high, and has fluctuated between a low of $7.22 and a high of $9.36 on the day [2][5]